Relay Therapeutics (NASDAQ:RLAY) Insider Peter Rahmer Sells 1,354 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 1,354 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total transaction of $11,441.30. Following the completion of the sale, the insider owned 276,610 shares in the company, valued at $2,337,354.50. This represents a 0.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, January 27th, Peter Rahmer sold 11,684 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08.

Relay Therapeutics Price Performance

RLAY stock opened at $7.71 on Friday. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.04. The company has a market cap of $1.34 billion, a P/E ratio of -4.41 and a beta of 1.55. The stock’s fifty day moving average price is $7.96 and its 200-day moving average price is $5.95.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, analysts expect that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Shares are trading up intraday, sitting above the 200‑day moving average—a technical signal some investors view as constructive. MarketBeat RLAY quote
• Neutral Sentiment: Despite the recent sales, insiders still hold large positions (many hundreds of thousands of shares), which reduces the likelihood of a meaningful shift in strategic control; the disclosures show percentage ownership declines but substantial remaining stakes. (See SEC filings linked below.)
• Negative Sentiment: CFO Thomas Catinazzo sold 1,695 shares at an average $8.45 on Jan. 28 (total ~$14.3k), and had also sold 13,820 shares at ~$7.62 on Jan. 27; these filings show a multi-day reduction in the CFO’s ownership. Catinazzo filings
• Negative Sentiment: Insider Peter Rahmer sold 1,354 shares at $8.45 (Jan. 28) and 11,684 shares at $7.62 (Jan. 27), reducing his stake by several percent—more insider selling that can weigh on sentiment. Rahmer filings
• Negative Sentiment: Insider Donald A. Bergstrom sold 2,686 shares at $8.45 and 18,895 shares at $7.62 across Jan. 27–28, cutting his position by ~4%. Large, clustered insider sales can amplify near‑term downward pressure. Bergstrom filings
• Negative Sentiment: Market commentary highlights recent weakness in RLAY (example: a note explaining a ~5.2% drop), which may reflect short‑term sentiment, sector dynamics, or news-driven selling; that coverage can push momentum lower even if fundamentals are unchanged. Why RLAY is down 5.18%

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. increased its position in shares of Relay Therapeutics by 130.4% during the second quarter. Franklin Resources Inc. now owns 394,122 shares of the company’s stock worth $1,364,000 after acquiring an additional 223,042 shares during the period. Congress Asset Management Co. raised its position in shares of Relay Therapeutics by 160.9% in the 3rd quarter. Congress Asset Management Co. now owns 408,842 shares of the company’s stock worth $2,134,000 after acquiring an additional 252,142 shares in the last quarter. Geode Capital Management LLC raised its holdings in Relay Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock worth $11,176,000 after purchasing an additional 159,548 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Relay Therapeutics by 8,553.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 16,702 shares of the company’s stock worth $58,000 after acquiring an additional 16,509 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Relay Therapeutics by 16.5% during the second quarter. Acadian Asset Management LLC now owns 794,619 shares of the company’s stock worth $2,747,000 after purchasing an additional 112,591 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RLAY. Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective for the company in a research note on Monday. Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $6.00 to $13.00 in a report on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.